X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
index medicus (93) 93
oncology (77) 77
male (71) 71
female (69) 69
middle aged (67) 67
life sciences (62) 62
chemotherapy (56) 56
aged (55) 55
respiratory system (55) 55
cancer (52) 52
lung cancer (48) 48
santé publique et épidémiologie (46) 46
lung neoplasms - drug therapy (42) 42
lung cancer, non-small cell (41) 41
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (38) 38
adult (37) 37
carcinoma, non-small-cell lung - drug therapy (36) 36
lung neoplasms - pathology (36) 36
care and treatment (33) 33
carcinoma, non-small-cell lung - pathology (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (28) 28
neoplasm staging (28) 28
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (27) 27
mesh: humans (26) 26
analysis (25) 25
france (25) 25
research (24) 24
lung neoplasms - mortality (23) 23
treatment outcome (23) 23
aged, 80 and over (21) 21
carcinoma, non-small-cell lung - mortality (21) 21
hematology, oncology and palliative medicine (21) 21
metastasis (21) 21
pulmonary/respiratory (21) 21
mesh: middle aged (20) 20
prognosis (19) 19
survival (19) 19
trial (19) 19
chronic obstructive pulmonary disease (18) 18
mesh: male (18) 18
non-small cell lung cancer (18) 18
cisplatin (17) 17
lung neoplasms (17) 17
management (17) 17
mesh : humans (17) 17
mesh: female (17) 17
cisplatin - administration & dosage (16) 16
docetaxel (16) 16
france - epidemiology (16) 16
medicine (16) 16
nsclc (16) 16
patients (16) 16
studies (16) 16
cancer therapies (15) 15
lung neoplasms - therapy (15) 15
mortality (15) 15
pemetrexed (15) 15
prospective studies (15) 15
therapy (15) 15
antineoplastic agents - therapeutic use (14) 14
carcinoma, non-small-cell lung - therapy (14) 14
cost-effectiveness (14) 14
erlotinib (14) 14
lung neoplasms - economics (14) 14
mesh: adult (14) 14
non-small-cell lung cancer (14) 14
oncology, experimental (14) 14
quality of life (14) 14
risk factors (14) 14
antineoplastic agents (13) 13
disease-free survival (13) 13
lung diseases, obstructive (13) 13
mesh : middle aged (13) 13
mesh: aged (13) 13
research article (13) 13
survival rate (13) 13
carcinoma, non-small-cell lung - economics (12) 12
cost analysis (12) 12
development and progression (12) 12
diagnosis (12) 12
follow-up studies (12) 12
gemcitabine (12) 12
immunotherapy (12) 12
medicine & public health (12) 12
mesh : male (12) 12
mesh: lung neoplasms (12) 12
mutation (12) 12
retrospective studies (12) 12
survival analysis (12) 12
bevacizumab (11) 11
carcinoma, non-small-cell lung (11) 11
copd (11) 11
cost-benefit analysis (11) 11
deoxycytidine - analogs & derivatives (11) 11
economic aspects (11) 11
guanine - analogs & derivatives (11) 11
mesh : female (11) 11
respiratory tract diseases (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0182798
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 07/2012, Volume 12, Issue 1, pp. 301 - 301
Journal Article
The Journal of Allergy and Clinical Immunology: In Practice, ISSN 2213-2198, 05/2019, Volume 7, Issue 5, pp. 1477 - 1487
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2011, Volume 6, Issue 9, p. e24870
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article